A dual-target circular mRNA program with a registered investigator-initiated trial (IIT) in relapsed/refractory multiple myeloma.
NCT07537049
PROGRAMMABLE RNA THERAPEUTICS
Programming immunity
in vivo with
circular mRNA.
Two therapeutic programs connect circular mRNA, cell-selective delivery, computational design and integrated CMC within one development system.
An AI-guided program connecting patient-specific neoantigen selection with circular mRNA vaccine design and manufacturing.
Planned expansion direction: Autoimmune diseases.
AI-NATIVE R&D
IN-HOUSE CMCCELL-SELECTIVE DELIVERYCIRCULAR mRNATWO LEAD DIRECTIONS · SELECTIVE EXPANSION
A focused pipeline.
Disciplined expansion.
In vivo CAR-T
Circular mRNA and cell-selective CellectLNP delivery support transient, non-integrating immune-cell programming in vivo.
Explore programNeoantigen Cancer Vaccine
AI ranks and optimizes patient-specific neoantigen combinations, linking tumor data to circular mRNA vaccine design and manufacturing.
Explore programOther In vivo mRNA Medicines
Programs advance selectively where programmable expression and targeted delivery can create differentiated therapeutic value.
Explore programSHARED DEVELOPMENT ENGINE
AI-enabled design · circular mRNA · cell-selective delivery · CMC & manufacturing
PROGRAMMABLE IMMUNITY
Patient data, RNA and manufacturing—
connected by evidence.
In vivo CAR-T delivers RNA instructions that program selected immune cells. Personalized cancer vaccines supply patient-specific antigen information to direct immune recognition. Both are supported by a shared translational system.
Neodiscovery.ai
Ranks and optimizes combinations of patient-specific neoantigens, linking tumor data to circular mRNA vaccine design.
Explore platform ↗CellectLNP Delivery
Designed to link antibody-directed targeting with biodistribution, intended-cell expression and tolerability.
Explore platform ↗Circular mRNA
A covalently closed RNA architecture developed for program-specific expression, product quality and manufacturability.
Explore platform ↗NEWS & PERSPECTIVES
Company progress.
Scientific perspective.
10 SEP 2026 · KEYNOTE
From in vivo CAR-T to AI-native PCV at BIOHK 2026
Byterna presented its programmable-immunity strategy, connecting transient in vivo CAR-T with AI-guided personalized neoantigen cancer vaccines.
View update ↗
JUN 2026 · 2025 AWARD PRESENTATION
2025 RNA Excellence Award
Presented to CEO Andy Xian Zeng in Singapore.
View update ↗
JUL 2026 · FINANCING
Pre-A financing completed
Advancing BR101 and platform priorities.
View update ↗INVESTORS
Backing long-horizon science.
Meet the investors and strategic partners supporting Byterna's mission.
CAREERS
Build at the AI–biology interface.
Join an R&D team integrating computational design, RNA engineering, targeted delivery and CMC to build proprietary in vivo mRNA medicines.
- 01AI Algorithm Engineer
- 02Data Scientist
- 03Project Lead, Pipeline R&D
- 04Research Scientist